ERG and prostate cancer: Recently, the potential prostate cancer biomarkers, such as prostate cancer antigen 3 (PCA3), TMPRSS2-ERG gene fusions and p501s (prostein), were investigated as auxiliary diagnosis candidates for prostate cancer [21-24].